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Abstract
Background Resection of hepatic metastases is indicated
in selected stage IV colorectal cancer (CRC) patients.
A minority will eventually develop pulmonary metastases
and may undergo lung surgery with curative intent. The
aims of the present study were to assess clinical outcome
and identify parameters predicting survival after pulmon-
ary metastasectomy in patients who underwent prior
resection of hepatic CRC metastases.
Methods We performed a retrospective analysis of 27
consecutive patients (median age 62 years; range:
33–75 years) who underwent resection of pulmonary
metastases after previous hepatic metastasectomy from
CRC in two institutions from 1996 to 2009. All patients
underwent complete resection (R0) for both colorectal and
hepatic metastases.
Results Median follow-up was 32 months (range:
3–69 months) after resection of lung metastases and
65 months (range: 19–146 months) after resection of pri-
mary CRC. Three- and 5-year overall survival rates after
lung surgery were 56 and 39%, respectively, and median
survival was 46 months (95% CI 35–57). Median disease-
free survival after pulmonary metastasectomy was
13 months (95% CI 5–21). At the time of last follow-up,
seven patients (26%) had no evidence of recurrent disease
and 6 of these 7 patients presented initially with a single
lung metastasis.
Conclusions Resection of lung metastases from CRC
patients may result in prolonged survival, even after pre-
vious hepatic metastasectomy. Yet, prolonged disease-free
survival remains the exception, and seems to occur only in
patients with a single lung lesion.
Introduction
Liver and lung are the most frequent sites of metastases
from colorectal cancer (CRC). Up to 25% of colorectal
cancer (CRC) patients initially present with metastatic
disease, usually confined to the liver, and another 25% of
patients will develop metachronous liver metastases after
primary tumor resection [1, 2]. Pulmonary metastases
develop in 8–10% of CRC patients, and may occur after
previous liver metastases [3, 4]. Although several novel
chemotherapeutic and biological agents have been devel-
oped, surgery is considered the most effective therapy for
selected patients with liver metastases [5]. Specialized
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centers have reported 5-year survival rates up to 50% after
liver resection for CRC metastases [6, 7]. Similarly, sur-
gical resection of synchronous or metachronous pulmonary
metastases has gained increased acceptance. Since 2000,
multiple series have investigated the outcome of CRC
patients who underwent resection of lung metastasis, with
5-year survival rates ranging from 24 to 68% [8–11].
However, the role of surgery is controversial for patients
presenting with both hepatic and pulmonary metastases. In
the literature, there are few series reporting the outcome of
more than 30 patients with resection of both hepatic and
pulmonary metastases [12–18]. In addition, these studies
were conducted at a time when hepatectomy was rarely
considered in patients with extensive liver metastasis and
before the modern era of chemotherapeutic and biological
agents. The aim of the present study was to assess the
clinical outcome after pulmonary metastasectomy in
patients who underwent prior resection of hepatic CRC
metastases and to identify predictors for survival.
Patients and methods
We performed a retrospective analysis of all CRC patients
who underwent pulmonary surgical resection with a cura-
tive intent in two different institutions (Geneva University
Hospital and Lausanne University Hospital) in Switzer-
land. Among 70 patients with pulmonary metastases who
underwent pulmonary metastasis resection, 27 patients had
previously undergone resection of hepatic metastases. All
of these patients were operated on since 1996 and they
constitute the subject of this retrospective study. Lung
surgery and liver metastases surgery were performed in the
Thoracic Surgery Unit and in the Visceral Surgery Unit of
both institutions. We included all patients with a histopa-
thological diagnosis of colorectal adenocarcinoma meta-
static to the lung who had undergone prior liver surgery.
The following parameters were recorded and considered
for statistical analysis: (1) patient characteristics; (2)
primary tumor characteristics (TNM stage, location, pre-
operative radiation therapy, adjuvant chemo-and/or che-
motherapy); (3) characteristics of liver metastases (number
and location, size of largest metastases, adjuvant chemo-
therapy, and extent of liver resection); (4) characteristics of
lung metastases (number and size of the largest metastasis,
type of resection [wedge, lobectomy or pneumonectomy],
involvement of mediastinal lymph nodes, adjuvant che-
motherapy, disease-free interval between primary tumor
resection and development of lung metastases, and unilat-
eral or bilateral distribution). The study was conducted in
accordance with institutional guidelines of the Ethics
Committee for Clinical Research of Geneva University
Hospital and Lausanne University Hospital.
Eligibility for surgical resection of lung metastases from
CRC after previous liver surgery was based on four criteria:
(1) control of primary tumor considered as achieved;
(2) absence of extrathoracic lesions at the time of lung sur-
gery; (3) possibility to perform a complete resection (R0) of
pulmonary metastases; and (4) adequate pulmonary reserve
to tolerate the planned resection. Follow-up was performed
in the Surgical Oncology Unit of both institutions, with
repeated clinical examination and thoracoabdominal CT
scan imaging once a year for 5 years to detect local or sys-
temic tumor recurrence. In addition all patients underwent
colonoscopy surveillance at 1, 3, and 5 years postcolectomy.
All patients received two to six cycles of chemotherapy
before liver resection, using a combination of oxaliplatin
[O], irinotecan (CPT-11[C]), 5-fluorouracil (5-FU) [F], and
leucovorin [L], according to the following doses and sche-
dule: oxaliplatin 70 mg/m2 on days 1 and 15, irinotecan
(CPT-11) 100 mg/m2 on days 8 and 22, 5-FU 2 g/m2/24 h
and leucovorin (LV) 30 mg on days 1, 8, 15, and 22, repe-
ated every 5 weeks. Seven patients had a similar regimen,
but with 5-FU/LV replaced with capecitabine (the oral
prodrug of 5-FU) 800 mg/m2 per day from day 1 to day 28.
One patient received a standard treatment with capecitabine
and oxaliplatin (capecitabine 2 g/m2, oxaliplatin 130 mg/m2
day 1, days 1–14, repeated every 3 weeks). The response to
chemotherapy was assessed after two to three cycles. Further
evaluations were obtained according to the clinical response
and surgical pattern of disease. More recently, patients were
treated with the addition of bevacizumab (Avastin) and
cetuximab (Erbitux) to complement the OCFL regimen.
Statistical analysis
The follow-up was complete for all patients. Frequency
distributions were obtained for descriptive patient vari-
ables. Kaplan–Meier methods were used to examine
relapse-free survival and overall survival. The association
between tumor relapse and death was explored in a Cox
proportional hazards model where relapse was a time-
dependent covariate: a patient switched from low-risk
status to high-risk status at the time of the relapse (not at
baseline). Simple Cox models were used to examine
associations between patient characteristics and risk of
death. Because of the low number of patients, no multi-
variate model was constructed. The analyses were per-
formed with SPSS version 17 (SPSS, Chicago, IL).
A P value \0.05 was considered statistically significant.
Results
The study sample included 27 patients (14 men, 13 women)
initially diagnosed with CRC who first underwent resection
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of liver metastases and then surgery for lung metastases.
The median age at the time of lung surgery was 62 years
(range: 33–75 years). Primary tumor location was pre-
dominantly the left colon (14 patients) and the rectum
(11 patients). Using the TNM classification, most patients
presented initially with an advanced local tumor stage
(stages III/IV: 18 patients). Less than half of patients pre-
sented initially with synchronous metastatic disease
(M0: 17 patients, M1: 10 patients). The clinical stage at
diagnosis was advanced for most patients (stage I: 2 patients;
stage II: 7 patients; stage III: 8 patients and stage IV: 10
patients). The clinical, pathological, and surgical character-
istics of the study population are summarized in Table 1.
The mode of development and the sequence of meta-
static spread are summarized in Fig. 1. Interval between
resection of primary tumor and that of liver metastases
ranged from 0 to 50 months (median: 11 months). Liver
locations were in the right lobe in 17 patients, in the left
lobe in four patients and in both lobes in six patients. The
median delay between primary tumor resection and surgery
for lung metastasis was 32 months (range: 0–100 months).
Twenty patients had a single lung metastasis; the others
had between 2 and 7 metastases. The median size of the
largest metastasis was 25 mm (range: 6–75 mm). The vast
majority of patients (74%) underwent pulmonary wedge
resections as a major lung resection. No patient had
simultaneous liver and pulmonary resection.
Follow-up was obtained for all patients until death
(11 patients) or last visit (16 patients). The median duration
of follow-up was 32 months (range: 3–69 months) after
lung surgery. During this period, 20 patients had a relapse
of the primary tumor, in the liver (5), lung (5), bone (4),
brain (1), or multiple sites (5). Ten of the 20 patients who
relapsed died, versus 1 of the 7 relapse-free patients.
Occurrence of relapse was a strong predictor of death. In a
proportional hazards model in which relapse was a time-
dependent covariate (i.e., the patient moved to the high risk
group only at the time of the relapse), tumor relapse was
associated with an almost nine-fold increase in the risk of
death (relative hazard 8.9, 95% CI 1.1–71.7). Three- and
5-year overall survival rates after lung surgery were 56 and
39%, respectively, and median survival was 46 (95% CI
35–57) months (Fig. 2). Median disease-free survival after
pulmonary metastasectomy was 13 (95% CI 5–21) months
(Fig. 3).
As an exploratory analysis, because of the small sample
size, we examined patient characteristics that may be
Table 1 Clinicopathological characteristics of 27 colorectal cancer









\60 years 11 41
[60 years 16 59










Metachronous metastasis 10 37
Number of pulmonary metastases
1 20 74
[1 7 26
Number of liver metastases
\3 19 70
[3 8 30
Type of liver resection
Wedge 7 26
Segmentectomy 11 41
Left hepatectomy 2 7
Right hepatectomy 7 26
Fig. 1 Sequence of hepatic and pulmonary metastases after the
diagnosis of colorectal cancer
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associated with mortality (Table 2). Three parameters were
associated with an average twofold increase in mortality:
(1) age [60 years; (2) primary tumor stage III/IV; and
(3) presence of multiple lung metastases, as opposed to a
single metastasis (Fig. 4). None of these associations
appeared, however, statistically significant.
Discussion
We report a series of 27 CRC patients treated with modern
chemotherapy (oxaliplatin, irinotecan, and biologic
agents), who underwent liver surgery after 1999, and then
subsequent lung metastasectomy. Our data indicate that
these patients may experience prolonged (median
46 months) survival. However, a majority (74%) of
Fig. 2 Overall survival after lung metastasectomy
Fig. 3 Relapse-free survival of patients with lung metastases








Male 6/14 1.0 (reference)
Female 5/13 1.1 (0.3–3.8)
Age 0.27
\60 years 3/11 1.0 (reference)
C60 years 8/16 2.1 (0.6–8.0)
Primary location 0.78
Colon 6/16 1.0 (reference)
Rectum 5/11 1.2 (0.4–3.9)
Tumor stage 0.40
1–2 2/9 1.0 (reference)
3–4 9/18 1.9 (0.4–9.0)
Time to first metastasis 0.44
0–6 months 7/14 1.6 (0.5–5.5)
[6 months 4/13 1.0 (reference)
Time from liver metastasis
to lung metastasis
0.49
0–24 months 5/16 0.7 (0.2–2.2)
[24 months 5/11 1.0 (reference)
Number of lung metastases 0.38
1 8/20 1.0 (reference)
2 or more 3/7 1.8 (0.5–7.1)
Size of largest lung
metastases
0.94
B25 mm 7/16 1.0 (reference)
[25 mm 4/11 1.0 (0.3–3.6)
Fig. 4 Survival in patients with single (solid line) or multiple
(dashed line) lung metastases
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patients developed tumor recurrence with short median
relapse-free survival (13 months). Six of seven patients
who were alive with no evidence of disease at last follow-
up had a single isolated lung metastasis. This group of
patients with limited CRC spread to the lung (a single
lesion less than 2 cm in size) may benefit the most from
pulmonary metastasectomy.
Surgical resection is rarely curative in CRC patients who
subsequently develop both hepatic and pulmonary metasta-
ses: most clinicians rightfully consider that metastatic spread
to more than one organ reflects the systemic nature of the
disease. Yet, in selected cases, resections of pulmonary and
hepatic metastases of CRC are increasingly considered as a
curative option. In our series, as in others [12], this approach
is now associated with median survival up to 4 years, even
though long-term relapse-free survivals remain exceptional.
The challenge is now to identify the group of patients which
will benefit from this aggressive sequential surgical
approach. Unfortunately, predictive factors for prolonged
disease-free survival in these patients are yet to be defined.
Various parameters have been associated with prolonged
survival in isolated pulmonary metastasectomy from
CRC including: (1) a long disease-free interval [19–22];
(2) prethoracotomy carcinoembryonic antigen (CEA) level
\5 ng/ml [23]; (3) a single isolated metastasis \3 cm in
size [24]; and (4) the absence of thoracic lymph node
invasion [25, 26]. In contrast, predictive prognostic factors
after both liver and lung metastases resection of CRC have
not been clearly defined in the literature. Miller et al. [12]
reported in 2007 the largest series of patients and identified
prognostic factors for improved survival: (1) disease-
free interval in-between metastases greater than 1 year,
(2) single liver metastasis, and (3) age less than 55. Others
reported that lung first metastases [15] and high CEA level
before metastasectomy [13] were prognostic factors of
worse outcome. In our series, mortality was increased by
twofold in patients with primary tumor stages III or IV and
presence of multiple lung metastases, but due to the small
sample size, results were not statistically significant.
Five-year survival rates after first metastasectomy
reported in various series ranged from 11 to 50% [12–18].
These different results are difficult to compare due to
probably better patient selection in a long inclusion period
and different tumor biology. Liver resection was generally
performed before 2000 in selected patients before the
improvement of perioperative care and surgical techniques.
Our results did not differ from the literature with 5-year
survival rate of 39% after lung metastasectomy. Interest-
ingly, a recent series indicates that patients who underwent
resection of both liver and lung colorectal metastases may
experience longer survival than patients who underwent
resection of liver metastases alone (5-year overall survival
rates 50% vs. 40%) [18].
In conclusion we report a series of highly selected CRC
patients with both liver and lung metastases and who bene-
fited from a modern chemotherapy regimen in addition to
surgery with a curative intent in both metastatic locations.
While resection of lung metastases from CRC may be
compatible with prolonged survival (even when patients
have undergone prior resection of liver metastases), it is clear
that the majority of patients will experience a recurrence
within 2 years after lung surgery and ultimately will die from
colorectal cancer. We observed that 6 of 7 patients who were
disease-free at the time of last follow-up presented with a
single, small (\2 cm) lung metastasis. Clearly, CRC patients
with this type of disease extension are good candidates for
pulmonary resection, even when they have previously
undergone resection of liver metastases.
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